July 25, 2019 – SEOUL, South Korea. The International Vaccine Institute (IVI) is pleased to announce that EuBiologics, IVI’s key partner in Korea, received a 900 million Korean won ($760,000) award from the RIGHT Fund for the development of a cholera conjugate vaccine. EuBiologics submitted a proposal for the development of the cholera conjugate vaccine in Dec 2018 in response to the RIGHT Fund’s very first Request for Proposals.
The Research Investment for Global Health Technology (RIGHT) Fund is the first public-private partnership between the Korean government, Korean life science companies, and the Bill & Melinda Gates Foundation. The RIGHT Fund was founded in July of 2018 to ensure that Korea’s outstanding global health R&D technologies are effectively used to help resolve healthcare disparities in developing countries.
EuBiologics is the lead institution for this cholera vaccine project, which will be conducted in collaboration with the Massachusetts General Hospital in Boston and IVI.
The cholera conjugate vaccine is the only injectable vaccine candidate in development and has the potential to induce robust immune responses and improve protection in children under the age of five. EuBiologics, who leads the project, is also planning to expand the indications by developing conjugate vaccines and combination vaccines for other diseases such as typhoid fever and shigellosis.
Dr. Ed Ryan from the Massachusetts General Hospital and Harvard Medical School, and his colleagues, are the original developers of the cholera conjugate vaccine and will provide the required technology for the project. EuBiologics will produce clinical trial materials in compliance with cGMP and conduct process optimization. The toxicology study will be pursued in the U.S., and EuBiologics will continue this development for evaluation in humans by filing an IND to the Ministry of Food and Drug Safety, South Korea. IVI will support the technology transfer between EuBiologics and the Massachusetts General Hospital.
The RIGHT Fund said it believes that this joint project represents an important next step towards the clinical validation of a new conjugation technology for a cholera vaccine with the potential to improve protection in children younger than five. EuBiologics will lead the collaboration and if successful, plans to assess the feasibility of introduction in Low and Middle Income Countries (LMICs) -where unmet need is the greatest.